History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and MEDI4736 or previous toxicity attributed to MEDI4736 or other PD-1 or PD-L1 directed therapy that led to drug discontinuation
History of allergic reaction attributed to compounds of similar chemical or biologic composition to the MEK inhibitor, trametinib
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel and/or both platinum-based chemotherapy agents are excluded; patient must be able to receive at least one of the two proposed chemotherapy regimens
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or other agents used in study, or history of severe hypersensitivity reaction to any monoclonal antibody
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib or bevacizumab
Patients with a history of allergic reactions attributed to compounds of similar composition, including macrolide and ketolide antibiotics, temsirolimus/other mTOR inhibitors, temozolomide or irinotecan are not eligible
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to LY2606368 or to its formulation are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) and/or rhIL-12 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and ramucirumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs (e.g. cisplatin)
History of allergic reactions attributed to compounds of similar chemical or biologic composition as the study agents
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
Patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or other agents used in the study
Patients must NOT have a history of allergic reactions attributed to compounds of similar chemical or biochemical composition to cisplatin, carboplatin, etoposide, temozolomide or capecitabine
History of allergic reactions attributed to compounds of chemical or biologic composition similar to palbociclib.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and atezolizumab; patients with a known hypersensitivity to olaparib or any of the excipients of the product
History of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to hetIL-15.
History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to the taselisib drug formulation or other agents used in this study
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to phenelzine or other monoamine oxidase inhibitors
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or trastuzumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, decitabine or SGI-110
History of allergic reactions attributed to compounds of similar chemical or biologic composition to afatinib or docetaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to GM-CSF
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sotatercept, lenalidomide, pomalidomide, or dexamethasone
Patients who have any history of allergic reaction(s) attributed to compounds of similar composition to temozolomide, pazopanib, their metabolites, or any component of their formulation are NOT eligible for participation
History of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ficlatuzumab or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab and trebananib including history of allergic reactions to bacterially produced proteins
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PT2385 are ineligible
Subject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to bavituximab
Patients with history of allergic reactions attributed to compounds of similar composition to pazopanib, irinotecan, or temozolomide are not eligible
Patients may not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib (including abemaciclib)
Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, everolimus or exemestane
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ramucirumab
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib are not eligible; AND/OR patients who have had prior exposure to compounds of similar chemical or biologic composition to palbociclib are not eligible hypersensitivity to any component of palbociclib are not eligible for participation
History of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ribociclib, T-DM1 (Cohort A)) and/or trastuzumab (Cohorts B and C) and/or fulvestrant (Cohort C)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PLX3397 or sirolimus
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or carboplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-P.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinib
History of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 or paclitaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib (BMN 673) or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, nab-paclitaxel, or other agents used in the study; previous grade 1 or 2 allergic reaction to cetuximab is permissible
History of allergic reactions/hypersensitivity attributed to compounds of similar chemical or biologic composition to tamoxifen, anastrozole, or fulvestrant or any of their ingredients
History of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus
History of allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition to anastrozole or letrozole
History of allergic reactions attributed to compounds of similar chemical or biologic composition to liposomal cytarabine or other agents used in study inclusive of known allergy to polyethylene glycol
History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin and/or rituximab
Known allergy to any of the study agents or to compounds of similar chemical or biologic composition are excluded (including other somatostatin analogs)
History of allergic reactions or adverse reactions (e.g., wound dehiscence) attributed to compounds of similar chemical or biologic composition to PLG or known hypersensitivity to GM-CSF, CPG or PLG
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991or other agents used in the study
Known history of allergic reactions attributed to compounds of similar chemical or biologic composition to fenretinide, such as 13-cis-retinoic acid, retinol, or all-trans-retinoic acid
History of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib or LY3300054.
Subjects with a history of hypersensitivity to compounds of similar biologic composition to atezolizumab or any constituent of the product
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MCS110, dabrafenib, or trametinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab or nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to BVD-523
Subjects with a history of hypersensitivity to compounds of similar biologic composition to atezolizumab or any constituent of the product
History of allergic reactions attributed to compounds, or any of its excipients, of similar chemical or biologic composition to osimertinib or selumetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclib
History of allergic reactions attributed to compounds of similar chemical composition to chemotherapy to be used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to daratumumab
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab
Women with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Tamoxifen.
EXPANDED ACCESS COHORT: History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or binimetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide (only for arm B)
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to monoclonal antibody treatment, any components used in the ramucirumab drug product (DP) preparation, irinotecan, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical composition to SY-1365
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gefitinib or osimertinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to LY3022855, vemurafenib, or cobimetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to apalutamide or docetaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or previous toxicity attributed to pembrolizumab or other PD-1 directed therapy that led to permanent drug discontinuation
History of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib or olaparib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or ganitumab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or cisplatin
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970 or irinotecan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib (XL184)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or gemcitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 (onalespib)
Patents with history of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to platinum based chemotherapy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vemurafenib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or IMGN853
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or venetoclax
Known hypersensitivity to MK-3475 (pembrolizumab) or history of allergic reactions to compounds of similar chemical or biologic composition to anti-PD1 or PD-L1 antibodies or entinostat
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to HMAs
History of allergic reactions attributed to compounds of similar chemical or biologic composition to merestinib
Participant has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ACTOplus Met XR
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ixazomib or lenalidomide
Participant with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of retinoids
History of allergic reactions attributed to compounds of similar chemical or biologic composition to prexasertib.
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to mifepristone or paclitaxel/nab-paclitaxel; patients with a history of mild infusion reactions with paclitaxel who were able to continue to receive paclitaxel with corticosteroid premedication will be eligible to participate, as these cases were likely related to cremaphor and not paclitaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents (cyclophosphamide, busulfan, pentostatin, sirolimus, MMF, granulocyte-colony stimulating factor [G-CSF]) used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in this study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to defactinib, pembrolizumab, gemcitabine, or other agents used in the study
Subject has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PROSTVAC or ipilimumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sertraline
Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib or everolimus
History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e. gentamicin)
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or other agents (R-CHOP) used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to INC280; excipients in the current formulation include microcrystalline cellulose, mannitol, sodium starch glycolate, magnesium stearate and colloidal silicon dioxide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or TMZ
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX-200 or other agents used in the study (e.g., imidazoles, quinolones)
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or docetaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or lenalidomide agents used in study, such as bortezomib or thalidomide, in addition to patients with known allergy to sulfobutyl ether beta-cyclodextrin (Captisol)
Known hypersensitivity or allergic reactions attributed to any compounds of similar chemical or biologic composition to the study medication, such as recombinant IL-12 or other monoclonal antibodies
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Combotox or other agents used in study agents
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, anetumab ravtansine or paclitaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MTX110 or gadolinium.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib, mirvetuximab soravtansine or monoclonal antibodies
History of allergic reactions attributed to compound of similar chemical or biologic composition to the agents used in this study.
History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to olaparib or its excipients
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide, CRLX101, or other agents used in study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the regimen
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents to be used in the cohort the subject will be enrolled into
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel or avelumab, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0 grade >= 3)
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ADI-PEG 20, gemcitabine, pegylated compounds, or other agents used in the study
History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells
Hypersensitivity to chemotherapy or history of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab, ibrutinib, ICE, Ave, or Uto
Has a history of allergic reactions attributed to the study treatments (AZD9150 or durvalumab), assigned chemotherapy agents, their compounds, or agents of similar chemical or biologic composition (e.g., antibody therapeutics)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients.
History of significant allergic reactions attributed to compounds of similar composition to SD-101 or BMS-986178
History of allergic reactions attributed to compounds of similar chemical or biologic composition to apatinib or pembrolizumab
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study
COHORT 3: ENDOMETRIAL CANCER: History of allergic reactions attributed to compounds of similar chemical or biologic composition to imipridones or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, cisplatin (for cohort 1), or cetuximab (for cohort 2)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents on this trial
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study vaccine components and any of the chemotherapy drugs (docetaxel, carboplatin, trastuzumab, pertuzumab)
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat, ruxolitinib, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide and blinatumomab or other agents used in study
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to anti-LAG-3, anti-CD137, and anti-PD1 are ineligible; the investigator brochures can be referenced for more information
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent or accompanying supportive medications.
The patient has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab and/or nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, carboplatin and paclitaxel or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients
History of allergic reactions attributed to compounds of similar chemical or biologic composition to EGF816 or gefitinib
Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to IACS-010759.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to leuprolide acetate, abiraterone acetate, prednisone or apalutamide or other agents used in the study.
History of known immediate or delayed hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to INCB039110, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO).
History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to avelumab or other agents used in the study (or monoclonal antibodies)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Vicinium or durvalumab or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab unless felt to be in the best interests of the patient in the opinion of the investigator
Patient must not have a history of allergic reactions like anaphylaxis attributed to compounds of similar chemical or biologic composition to meclizine such as antihistamine drugs.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to fostamatinib or paclitaxel; patients who are able to tolerate paclitaxel on a desensitization protocol will be allowed
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or mifepristone
History of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AZD8186 or docetaxel or to docetaxel itself
Patients with a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or T-DM1
History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel or carboplatin
Known severe hypersensitivity to selumetinib or olaparib, their comparators, or combination medications or any excipient of these medicinal products, or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or olaparib, or their comparator
History of allergic reactions attributed to compounds of similar chemical or biologic composition to blinatumomab or pembrolizumab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan, other topoisomerase inhibitors or gadolinium compounds
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to HMAs
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lamivudine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to zydelig
History of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab (anti-EGFR).
History of allergic reactions attributed to compounds of similar chemical or biologic composition to anetumab ravtansine or MK-3475 (pembrolizumab)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, carboplatin, pembrolizumab, or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel including to other drugs formulated in cremophor(R) EL (polyoxyethylated castor oil)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, topotecan, gadolinium, or lipids
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide are not eligible
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to denosumab are not eligible (i.e. same class of drugs) (Note: prior bisphosphonates are allowed; patients could have received bisphosphonates or be bisphosphonate-naive; patients who were previously on bisphosphonates can be enrolled in the study, as long as they have a wash-out period of 2 weeks prior to registration)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy agents in this study (if necessary)
Known hypersensitivity to poziotinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to poziotinib
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to mistletoe
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-DOTA-tyr3-octreotide, Octreoscan, 68Ga-octreotide, or 131I-MIBG
History of allergic reactions attributed to compounds of similar chemical or biologic composition to clarithromycin or taxanes
History of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1127 (varlilumab) and/or nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
History of allergic reactions attributed to compounds of chemical or biologic composition similar to palbociclib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib or nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or abiraterone
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or pemetrexed and cisplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab are not eligible; known hypersensitivity to any excipients of pembrolizumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, decitabine or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to hydroxychloroquine or received HCQ in the past six months
History of allergic reactions attributed to compounds of similar chemical or biologic composition to fosbretabulin
Hypersensitivity to BV or history of allergic reaction attributed to compounds of similar chemical or biologic composition of BV
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pevonedistat or decitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to IL-2
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib and blinatumomab or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin
Known hypersensitivity to compounds of similar chemical composition to BMX-001
Known allergy to compounds of similar chemical or biologic composition to nivolumab
Has a history of allergic reactions attributed to the study treatments (AZD9150 or MEDI4736), their compounds, or agents of similar chemical or biologic composition (eg, antibody therapeutics)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TVB-2640
History of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in study
History of allergic reactions attributed to compounds of chemical or biologic composition similar to interferons or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide and/or TG02
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or indomethacin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab, cisplatin, carboplatin, or etoposide
Patients with known allergy to eggs or to compounds with a similar chemical or biologic composition to PROSTVAC or nivolumab
History of allergic reactions attributed to compounds of similar composition to SD-101 or ibrutinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to daunorubicin
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, letrozole, trastuzumab, any other aromatase inhibitor, any other monoclonal antibody, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, carboplatin or cisplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or talazoparib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab including any history of severe allergic reactions to monoclonal antibody therapy
Patients with a history of allergic reactions attributed to or intolerance to compounds of similar chemical or biologic composition to either CB-839 or capecitabine; if capecitabine has been received previously, must have tolerated at least an equivalent dose to the dose to be administered at their assigned dose level
Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin and pemetrexed
History of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor
History of allergic reactions attributed to compounds of similar chemical or biological composition to rebastinib or other agents used in the study (e.g., Cremophor)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to blinatumomab
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab are not eligible AND/OR patients who have had prior exposure to compounds of similar chemical or biologic composition to pembrolizumab are not eligible
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BCG are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to abiraterone or PDMX1001/niclosamide
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI3475 are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cesium 131 or other agents used in this study
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to lenvatinib and/or paclitaxel
History of allergic reactions attributed to fluorouracil (5-FU), leucovorin, irinotecan or oxaliplatin or to compounds of similar chemical or biologic composition
History of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent or other agents used in the study
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: History of allergic reactions attributed to compounds of similar chemical or biologic composition to CRLX101 and/or olaparib or other agents used in study
History of allergic reaction to compounds of similar chemical or biologic composition to cytarabine
Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to IRX5183
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or irinotecan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib and brentuximab vedotin (BV)
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition as obinutuzumab or ibrutinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ramucirumab or nab-paclitaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib
Known allergy to compounds of similar chemical or biologic composition to nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to methotrexate, vinblastine, doxorubicin or cisplatin or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib, temozolomide, or dacarbazine
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to DHEA or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine or bevacizumab
History of allergic reactions attributed to thalidomide, lenalidomide, or other compounds of similar chemical or biologic composition to pomalidomide or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)
History of allergic reactions attributed to Noni or other compounds of similar chemical or biologic composition to Noni, or the inactive components present in Noni capsules; uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any psychological, familial, sociological or other concomitant condition that would not allow adequate compliance with the study protocol
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or other agents used in the study
A history of allergic reaction attributed to compounds of similar chemical or biologic composition to fluorouracil (5FU), oxaliplatin, or leucovorin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or bortezomib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, methotrexate, gemcitabine or other agents used during the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BVD-523, gemcitabine, nab-paclitaxel, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to dexrazoxane or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab, paclitaxel or carboplatin
Subjects with a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to DS3032b
PHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or tremelimumab, or other agents used in study
PHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or tremelimumab, or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to methoxyamine or to pemetrexed or cisplatin
History of allergic reactions, intolerance or hypersensitivity attributed to compounds of similar chemical or biologic composition to TRC105 and/or everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological component
History of allergic reactions attributed to compounds of similar chemical or biologic composition to leflunomide or cholestyramine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to (study agent) or other agents used in study
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736, olaparib, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHistory of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736, cediranib, or to other humanized monoclonal antibodies; known history of anaphylaxis, angioedema, laryngeal edema, serum sickness, or uncontrolled asthma
History of allergic reaction attributed to compound(s) of similar chemical or biologic composition as ARQ 092, carboplatin, paclitaxel, or anastrozole
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to indoximod, docetaxel, or other agents used in the study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec
History of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the pre- or post-transplant regimen
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABRAXANE or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed
Patients with history of allergic reactions attributed to compounds of similar chemical; or biologic composition to vorinostat or temsirolimus are not eligible
History of hypersensitivity reaction specifically attributed to compounds of similar chemical or biologic composition to 5-FU, leucovorin, capecitabine or bevacizumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to mitomycin C or other agents used in the study
Prior allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or trametinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to basiliximab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or metformin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to VOR or HCQ
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to nintedanib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients
History of allergic reactions attributed to Flagyl (metronidazole), which has a chemical structure similar to EF5
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or ziv-aflibercept
History of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine and or busulfan or other agents used in this study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or carboplatin
History of known immediate or delayed hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to AT13387, dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to etoposide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in this study
History of allergic reactions attributed to compounds of similar biologic composition to M032 or to IL-12
History of allergic reactions attributed to compounds of similar chemical or biologic composition to propranolol
History of allergic reactions to compounds of similar composition to either CDX-301 or poly-ICLC
History of prior allergic reactions attributed to compounds of similar chemical or biologic composition as capecitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, oxaliplatin, irinotecan or gemcitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, docetaxel, vorinostat, or granulocyte colony-stimulating factor (G-CSF)
History of allergic reactions attributed to compounds of similar chemical composition agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to anakinra or other agents used in study; known hypersensitivity to Chinese hamster ovary (CHO)-cell derived biologics or any components of anakinra
History of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to DOPC, Magnevist, or fluorodeoxyglucose (FDG)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin for patients who will receive chemotherapy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to IPdR
History of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the experimental agents or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9291 (osimertinib) or bevacizumab
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, lomustine, vincristine (vincristine sulfate) or cyclophosphamide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin
EXCLUSION CRITERIA FOR REGISTRATION: history of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin
History of allergic reactions attributed to compounds of similar chemical or biological composition to Valproic Acid
History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and durvalumab or previous toxicity attributed to durvalumab or other PD-1 or PD-L1 directed therapy that led to drug discontinuation
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TCN-PM
History of severe allergic reactions or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to STA-9090 (eg. Polyethylene glycol [PEG] 300 and Polysorbate 80)
History of allergic reactions to compounds of similar chemical or biologic composition to talactoferrin or the chemotherapy drugs
History of allergic reactions attributed to compounds of similar chemical composition to IHL-305
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cenersen.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib and/or nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to agent(s) or other agents used in study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorolanib, nivolumab, or pembrolizumab (as applicable), any monoclonal antibody, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to CPI-613 or docetaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil or imiquimod
History of allergic reactions attributed to compounds of similar chemical or biologic composition to CPI-613
History of allergic reactions attributed to compounds of similar chemical or biologic composition;
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs; patients who have previously received either clofarabine or bortezomib will be excluded
Patients with known hypersensitivity to nintedanib or 5-azacitidine or who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nintedanib or 5-azacitidine are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenvatinib
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BMS-813160, nivolumab, gemcitabine, paclitaxel, nab-paclitaxel, or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to poly-ICLC or other agents used in the study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab or any excipient or any egg products
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MCS110, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or PDMX1001/niclosamide
A history of allergic reactions or significant toxicity attributed to compounds of similar chemical or biologic composition to anti-CD20 mAbs, anti-PD-1 mAbs, or TLR agonists.
Participants who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to birinapant or its constituents
History of allergic reactions attributed to compounds of similar chemical or biologic composition to regorafenib or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to WP1066
History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX970), cisplatin, or gemcitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or sorafenib
Patients with a history of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 are ineligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nelfinavir
History of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to measles virus vaccination
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib and AT13387 used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to XL184
Subjects with history of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 or carfilzomib, lenalidomide, or dexamethasone
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to BAL101553 are ineligible
History of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in this study
History of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PLX3397 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to quinacrine, capecitabine or fluorouracil
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax or vistusertib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to tazemetostat
Patients with a known hypersensitivity to olaparib or any of the excipients of the product; history of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102 or TMZ
History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib, cediranib, carboplatin, cisplatin, or etoposide
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to either paclitaxel or ricolinostat; patients who require administration of paclitaxel through a desensitization procedure are not eligible for this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib and MM-398; if patients have a history of allergic reactions to compounds resembling MM-398, they will be excluded from participating in the FMX MRI study, if applicable
History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970, carboplatin, gemcitabine or to these specific compounds
History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib (difficulty breathing, lip swelling, itching or rash)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 and ziv-aflibercept
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or cisplatinum or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to briciclib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs (e.g. cisplatin, paclitaxel)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or belinostat
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
History of allergic reactions to compounds with similar biologic or chemical composition to pembrolizumab or radium-223
History of allergic reactions attributed to compounds of similar chemical or biologic composition to CDX-1401 or CDX-301 or poly-ICLC
History of allergic reactions attributed to compounds of similar chemical or biologic composition to CYT107
History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to metformin, ritonavir or any of their ingredients
Have history of allergic reactions attributed to compounds of similar chemical or biologic composition to taxanes (docetaxel or paclitaxel) or cyclophosphamide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to G-CSF/filgrastim (Escherichia [E] coli producing cell line), plerixafor or busulfan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ethacrynic acid or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Dex or Enza
History of allergic reactions attributed to compounds of similar chemical or biologic composition to G-CSF/filgrastim (E. coli producing cell line) and plerixafor
History of allergic reactions attributed to compounds of similar chemical or biologic composition to either 5-FU/capecitabine or interferon
Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775
PHASE II: Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel, gemcitabine or AZD1775
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 or cyclosporine A or their excipients
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TPI 287
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 or bevacizumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, nab-paclitaxel or enzalutamide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to HDACI, TLR-agonist, or patients with known history of pre-existing auto-immune disease
History of allergic reactions attributed to compounds of similar chemical or biologic composition to INCB024360, MELITAC 12.1, or other vaccine components
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or ipilimumab
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib, bortezomib or decitabine that are not easily managed
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PF-04449913
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, temozolomide and dacarbazine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat
History of allergic reactions attributed to compounds of similar chemical or biologic composition to digoxin
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study, including Cremophor, carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar chemical or biologic composition are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition ipilimumab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib, erlotinib or gemcitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition (i.e. ethanol) to XL888 or vemurafenib (i.e., ethanol)
Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the study
PHASE II: Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition of decitabine, cytarabine or daunorubicin
History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells (i.e. gentamicin)
History of allergic reactions attributed to compounds of similar chemical or biologic composition of those used in this study
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to IL-12 or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib (ABT-888) or cyclophosphamide used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (i.e. thalidomide)
Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to lenalidomide, bortezomib and/or dexamethasone
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to afatinib and/or cetuximab
History of allergic reactions attributed to compounds of similar chemical composition to afatinib
Poor tolerability or known allergy to lenalidomide, bortezomib and/or dexamethasone or compounds that have similar chemical or biologic composition to these study drugs
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib
Patient must have no history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to VX-970
History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or cisplatin
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991, cetuximab, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or cisplatin
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD 1775 (MK-1775) or gemcitabine
History of Grade 3 or 4 allergic reactions attributed to compounds of similar chemical or biologic composition as MSC2363318A
Subjects with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin. Compounds of similar composition include Auristatin PHE as an anti-fungal agent, Auristatin PE (TZT-1027, Soblidotin, NSC-654663) as an anti-tumor agent and Symplostatin 1 as an anti-tumor agent.
SUB-PROTOCOL AIM A: History of allergic reactions attributed to compounds of similar chemical or biologic composition including macrolide (e.g. azithromycin, clarithromycin, dirithromycin, and erythromycin) and ketolide antibiotics
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, fludarabine, or other agents used in the study.
No history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib, lenalidomide or rituximab or hypersensitivity to murine proteins or to any component of rituximab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or rapamycin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to mitomycin-C or 5-fluorouracil
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or HCQ
History of allergic reactions attributed to compounds of similar chemical or biologic composition to daunorubicin or cytarabine
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI4736 or other agents used in the study
History of allergic reactions attributed to compounds or similar chemical or biological composition to ibrutinib
History of allergic reactions attributable to compounds of similar chemical or biologic composition to ibrutinib or any component of pneumococcal, influenza and DTaP vaccines
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to poly-ICLC or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to mocetinostat or brentuximab vedotin
History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, Taxotere, Xeloda, cisplatin, or irinotecan
Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managed
History of allergic reactions attributed to compounds of similar chemical or biologic composition to hydroxychloroquine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dacomitinib
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or any of the components of the vaccine being administered as part of this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, bortezomib or rituximab
History of allergic reactions attributed to compounds of similar chemical or biological composition to metformin or oxaliplatin or fluorouracil (5-FU)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232 or decitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab; prior hypersensitivity reactions to anti-CD20 therapy or anti-CD30 therapy is not an exclusion criterion
History of allergic reaction(s) attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, irinotecan, or oxaliplatin
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab or other agents used in this study
Patients who have a history of allergic reactions or hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab and/or humanized antibodies are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or atezolizumab
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or lenalidomide
Patients with a history of allergic reactions attributed to bevacizumab or to compounds of similar chemical or biologic composition to nivolumab or bevacizumab are excluded
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab, cytarabine, bendamustine or other agents used in the study
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab are not eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to poxviral vaccines (e.g., vaccinia vaccine)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTA-JR11 as assessed from medical records
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MGE
Subjects with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the product
Subjects with a history of hypersensitivity to compounds of similar biologic composition to durvalumab or any constituent of the product
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 are not eligible; known hypersensitivity to any excipients of MK-3475
History of allergic reactions attributed to compounds of similar chemical or biologic composition to GEN-1 or other agents used in this study.
Known allergy to any of the treatment components including a history of allergic reactions attributed to compounds of chemical or biological composition similar to olaratumab.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib and/or bazedoxifene
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PM01183 or trabectedin (Yondelis, ET-743)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201 or its excipients
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9150
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to KPT-330 or other agents used in the study
Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to dexamethasone, boron or mannitol
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to tosedostat or capecitabine or other agents used in the study
Participants may not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
Patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PBI-05204 (i.e., cardiac glycoside compounds).
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, including but not limited to established allergic reaction to benzodiazepines, 5-FU (fluorouracil), leucovorin (leucovorin calcium) or oxaliplatin
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to IL-2
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
Patient has a history of allergic reactions to compounds of similar chemical or biological composition to buparlisib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, cetuximab, and/or bevacizumab that led to discontinuation of those agents
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or nab-paclitaxel or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to elotuzumab or lenalidomide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or omega-3 fatty acids
Patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475
Prior treatment with or allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinib
Patients must not have a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine or temsirolimus
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temsirolimus or perifosine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to crizotinib or enzalutamide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine and eribulin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to X-82, docetaxel, or granulocyte colony stimulating factors
History of allergic reactions attributed to compounds of similar chemical or biologic composition to LDE 225 or everolimus in the study or other rapamycin analogs (e.g. sirolimus, temsirolimus)
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or idelalisib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin or docetaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to curcumin or vitamin D or other agents used in this study
Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managed
History of allergic reactions or idiosyncrasy attributed to progestins or compounds of similar chemical structure to sodium cridanimod or lidocaine;
Research participants with a history of allergic reactions attributed to compounds of similar chemical or biological composition to cetuximab
Patients with known grade 2 or greater allergic reactions attributed to compounds of similar chemical or biologic composition to mifepristone, carboplatin, or gemcitabine are ineligible for study enrollment
PHASE I: History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
PHASE II: History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide (e.g. lenalidomide, thalidomide) or other agents used in study
History of allergic reactions to compounds of similar chemical or biological composition to T DM1 or ONT-380, except for a history of Grade 1 or Grade 2 Infusion Related Reaction to trastuzumab which has been successfully managed.
Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to lenalidomide, bortezomib, panobinostat and/or dexamethasone
History of allergic reactions attributed to compounds of similar chemical or biologic composition to trametinib monotherapy or trametinib in combination with GSK2141795
History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, azacitidine, or nivolumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib.
Participants who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to neratinib or fulvestrant
History of allergic reactions attributed to lenalidomide or compounds of similar chemical or biologic composition to lenalidomide including thalidomide
PART B: History of allergic or severe reactions attributed to compounds of similar chemical or biologic composition to ponatinib
History of allergic reactions to compounds of similar chemical composition to the study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or other drugs formulated with polysorbate 80
History of grade 3 or 4 allergic reactions attributed to compounds of similar chemical or biologic composition to ARRY-380 or trastuzumab
History of allergic reaction attributed to compounds of similar chemical or biologic composition to eribulin mesylate, trastuzumab or pertuzumab, which cannot be managed by premedication
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study including dimethyl sulfoxide (DMSO)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or lenalidomide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanib or enzalutamide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or poxviral vaccines (e.g., vaccinia vaccine)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or poxviral vaccines (e.g., vaccinia vaccine)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AUY922
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to doxorubicin or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to midostaurin and/or decitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine
Patients must NOT have history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouricil, irinotecan, oxaliplatin, or losartan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, trastuzumab, pertuzumab; patients with minor (grade 1 or 2) allergic reactions to these agents, controlled with standard supportive measures, are eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel or tryptophan containing substances. This would include L-tryptophan or 5-hydroxy-tryptophan supplements. Also patients with a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80 are excluded.
History of allergic reactions attributed to, or intolerance of, or other significant toxicity with, compounds of similar chemical or biologic composition to X-82 or everolimus
REGISTRATION EXCLUSION CRITERIA: History of allergic reactions attributed to compounds of similar chemical or biologic composition to trastuzumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab
History of allergic reactions attributed to compounds of similar chemical or biological composition as ARQ 087
History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide (including thalidomide), clarithromycin, or melphalan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to FLT
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib, cetuximab, or other agents used in the study
Patients must not have any of the following conditions:\r\n* Recent major surgery, hormonal therapy (other than replacement) or chemotherapy, within 4 weeks prior to entering the study or those who have not recovered from the adverse events of treatment\r\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy on this trial
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the chemotherapy used in the study
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to either MLN8237 or nab-paclitaxel, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 386 or the anti-VEGF agent used in study
History of allergic reactions attributed to 5FU, leucovorin, irinotecan or oxaliplatin or to compounds of similar chemical or biologic composition.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dexanabinol
History of allergic reactions attributed to compounds of similar chemical or biologic composition to topotecan or irinotecan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to black cohosh
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5-fluorouracil, irinotecan, or oxaliplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or abiraterone
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to fulvestrant or ganetespib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to fluorouracil (5-FU), capecitabine, oxaliplatin, leucovorin, bevacizumab, and/or vitamin D3
History of allergic reactions attributed to compounds of similar chemical or biologic composition to neratinib (or to capecitabine for cohorts 3a/3b)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine and hydroxychloroquine (HCQ)
Subjects with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib or other agents used in the study
History of allergy or reaction attributed to compounds of chemical or biologic composition similar to those of MEDI-573 or AI
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sonidegib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to plerixafor or bevacizumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition of BKM120, BYL719, capecitabine (including fluorouracil), trastuzumab or lapatinib
History of allergic reactions attributed to compounds of similar chemical or biological composition to lapatinib or trastuzumab; however, patients with a history of infusion reaction to trastuzumab which was controlled with premedication on subsequent infusions without a recurring infusion reaction are eligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AMG 232
History of allergic reactions to palbociclib or attributed to compounds of similar chemical or biologic composition to palbociclib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib maleate or olaparib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PF-00299804
History of allergic reactions attributed to compounds similar in chemical or biological composition to vorinostat or other agents used in this study
History of allergic reactions to compounds of similar chemical composition to the study drugs (docetaxel, cisplatin, carboplatin, erlotinib or their excipients), or other drugs formulated with polysorbate 80
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or other agents used in study
Known or suspected allergy to any recombinant human antibodies, or compounds of similar chemical or biologic composition to sorafenib or any of the drugs in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to BMN673 (talazoparib)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ganetespib or other agents used in study; history of severe allergic or hypersensitivity reactions to taxanes
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or idarubicin or cytarabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan, 5-FU, leucovorin or any of the products to be administered during dosing
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to platinums, taxanes or fluoropyrimidines
History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or belinostat
History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan or selinexor
History of allergic reactions attributed to compounds of similar composition to SD-101 or ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] antibodies)
Prior allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine (gemcitabine hydrochloride) or cisplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-1775 or cisplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib or clindamycin (topical agent for potential skin toxicity)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MEK162, anthracycline, or cytarabine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat, azacitidine, mannitol, irinotecan, docetaxel, pemetrexed, or gemcitabine, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Sunphenon 90 DCF-T or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 3-AP (triapine) or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to tretinoin or lithium carbonate or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 or other agents used in this study
Subjects with history of hypersensitivity to compounds of similar chemical or biologic composition of XILONIX™.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to peg-IFN?-2b
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin and paclitaxel or other agents used in the study are excluded
History of allergic reactions attributed to compounds of similar chemical or biologic composition to SS1(dsFv)PE38
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide, gemcitabine or carboplatin, or other agents used in study
ERLOTINIB HYDROCHLORIDE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib (erlotinib hydrochloride)
SELUMETINIB ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD6244 (selumetinib)
AKT INHIBITOR MK2206 ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 (Akt inhibitor MK2206)
LAPATINIB DITOSYLATE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
SUNITINIB MALATE ARM: History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sEphB4-HSA or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MPDL3280A, carboplatin, or paclitaxel
Patient with history of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to enzalutamide, carboplatin, or paclitaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib and/or onalespib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to onalespib or AT7519M
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or temsirolimus
History of allergic reactions attributed to compounds of similar chemical or biologic composition to calcitriol, ketoconazole, or other agents used in study
Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to belinostat, including hydroxamate compounds or arginine
Patients with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin; compounds of similar composition include auristatin PHE as an anti-fungal agent, auristatin PE (TZT-1027, Soblidotin, NSC-654663) as an anti-tumor agent and symplostatin 1 as an anti-tumor agent
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonate
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, oxaliplatin, fluorouracil (5-FU), docetaxel, or irinotecan
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dinaciclib or to MK-2206
Patients with history of allergic reactions attributed to compounds of similar composition to sirolimus, cyclophosphamide, or topotecan are not eligible
History of allergic reactions attributed to compound of similar chemical or biologic composition to the agent(s) used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, or nab-paclitaxel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the agent used in study.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) or other agents used in this study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine (gemcitabine hydrochloride) or cisplatin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or R-ICE
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MVA-brachyury-TRICOM or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to tivozanib
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan HCl for injection (propylene glycol-free), Captisol, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide, everolimus, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206
Known hypersensitivity/history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus or fulvestrant.
Known hypersensitivity to ipilimumab or history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Cabazitaxel, or to drugs formulated with polysorbate 80.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to levocetirizine, capecitabine, bevacizumab, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition as TG02 citrate.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD-101 or Zevalin or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pioglitazone
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib and ipilimumab
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or AZD1775 (MK-1775) are ineligible; the AZD1775 (MK-1775) investigator brochure and the temozolomide package insert can be referenced for more information
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib and its excipients.
Known severe hypersensitivity to selumetinib or any excipient of selumetinib or history of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to panitumumab
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ARQ 197 or temsirolimus
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vemurafenib or leflunomide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN8237, including but not limited to established allergic reaction to benzodiazepines
History of allergic reactions attributed to compounds of similar chemical or biologic composition to RAD001 or SOM230 (pasireotide)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents used in study (including hypersensitivity to paclitaxel, Cremophor, or platins)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or hydroxychloroquine
The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to that of cixutumumab or to octreotide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pembrolizumab or other agents used in the study
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to volasertib or VSLI are not eligible
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to rociletinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to BMN 673 and AT13387 used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pacritinib or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to melphalan, cyclophosphamide, or other agents used in the study
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed (pemetrexed disodium), 5-FU (fluorouracil), leucovorin (leucovorin calcium) or oxaliplatin, or other agents used for premedication in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, nab-paclitaxel or temozolomide
History of allergic reactions attributed to compounds of similar chemical or biologic composition to donepezil; hypersensitivity to donepezil
History of allergic reaction attributed to compounds of similar chemical or biologic composition to paclitaxel, which cannot be managed by premedication
Patients must not have a known history of allergic reactions attributed to compounds of similar chemical or biologic composition
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 (pembrolizumab) and interferon-gamma; patients who are hypersensitive to Escherichia (E). coli are also excluded
History of allergic reactions attributed to compounds of similar chemical or biologic composition to eribulin mesylate or pembrolizumab
History of allergic reactions attributed to tamoxifen or compounds of similar chemical or biologic composition
Subject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.
History of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab; known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 NCI CTCAE version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to CUDC-907
History of allergic reactions attributed to compounds of similar chemical or biologic composition to apalutamide, abiraterone acetate, or other study drugs
Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to sildenafil or phosphodiesterase-5 (PDE5) inhibitors such as vardenafil (Levitra) and tadalafil (Cialis) are not eligible.
Subjects with known hypersensitivity or other allergic reactions attributed to compounds of similar biologic composition to netupitant, palonosetron, dexamethasone, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to amide local anesthetics, acetaminophen or dexamethasone
History of severe (i.e. anaphylactic) allergic reactions attributed to compounds of similar chemical or biologic composition to glucocorticoids and other component of R-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cadaveric component, i.e. Flex HD
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel not responsive to traditional desensitization procedures
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Adriamycin, dacarbazine, or brentuximab
History of hypersensitivity attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) or osimertinib (AZD9291)
Known sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition entinostat, nivolumab, or ipilimumab; history of severe hypersensitivity reaction to any monoclonal antibody
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to naltrexone
No investigational agent, so no exclusion requirements regarding history of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational agent or device
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin or other agents used in the study
Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonate
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib
History of allergic reactions to yeast or attributed to compounds of similar chemical or biologic composition to Gardasil 9 HPV vaccine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestane
History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib (Tarceva)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 4-OHT gel
History of allergic reactions attributed to compounds of similar chemical or biologic composition to INO-8000 and INO-9012
History of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to simvastatin (i.e., other statin medications)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to NeuVax
History of allergic reaction to aspirin or attributed to compounds of similar chemical or biologic composition to aspirin, including other nonsteroidal anti-inflammatory drugs (NSAIDs)
History of allergic reaction to zileuton or attributed to compounds of similar chemical or biologic composition to zileuton
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MUC1/Poly?ICLC
History of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to simvastatin (i.e., other statin medications)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to WOKVAC
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Avmacol
History of allergic reactions attributed to compounds of similar chemical or biologic composition to bexarotene gel, oral or topical retinoids
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Gardasil or Gardasil 9
History of allergic reactions or intolerance attributed to aspirin or compounds of similar chemical or biologic composition
History of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea or EGCG
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Meriva
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of alendronate and other bisphosphonates
Documented history of allergic reactions attributed to compounds of similar chemical or biologic composition to buproprion
History of allergic reactions attributed to compounds of similar chemical or biologic composition to aspirin
Participants must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition of iloprost
History of adverse effects, intolerance, or allergic reactions attributed to compounds of similar chemical or biologic composition to pravastatin (i.e., other statin medications)
History of allergic reactions or hypersensitivity attributed to denosumab or any components of denosumab or compounds of similar chemical or biologic composition to denosumab, such as other RANKL inhibitors
History of allergic reactions attributed to compounds of similar chemical composition to Polyphenon E (or green tea), or intravenous contrast that is required for CT scan
History of allergic reactions attributed to compounds of similar chemical or biologic composition of PROSTVAC
Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to berberine will be excluded
History of allergic reactions attributed to compounds of similar chemical or biologic composition to telapristone (i.e. other progesterone antagonists)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PFE
A history of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen
History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or other agents used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Polyphenon E, tea, or any of the inactive ingredients present in the active or placebo drug products, including gelatin capsules
History of allergic reactions attributed to compounds of similar chemical composition to the study agents
History of allergic reactions attributed to compounds of similar chemical composition to YF476
History of allergic reactions attributed to compounds of similar chemical or biologic composition of GARDASIL 9 (recombinant human papillomavirus nonavalent vaccine), including yeast allergy
History of allergic reactions attributed to aspirin or compounds of similar chemical or biologic composition to the study agent
History of allergic reactions attributed to compounds of similar chemical or biological composition to aspirin, NSAIDs, cyclooxygenase-2 (COX2) inhibitors
History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabazitaxel or other drugs formulated with polysorbate 80; or abiraterone acetate
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MLN0128 (TAK-228) are ineligible
History of allergic reactions attributed to compounds of similar chemical or biologic composition to romidepsin, including cyclic tetrapeptide compounds
History of allergic reactions attributed to compounds of similar chemical or biologic composition to DHA or corn/soy oil in placebo agent
History of allergic reaction to aspirin or attributed to compounds of similar chemical or biologic composition to aspirin, including other nonsteroidal anti-inflammatory drugs (NSAIDs)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to linaclotide
Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of retinoids
Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-FES
Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-fluorothymidine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to PBR
History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or FMISO
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FLT or FDG are NOT eligible
Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FES are NOT eligible.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to demeclocycline
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in study
SURGICAL ARM: history of allergic reactions attributed to compounds of similar chemical or biologic composition to tetracyclines
History of allergic reactions attributed to compounds of similar chemical or biologic composition to copper Cu 64 anti-CEA monoclonal antibody M5A (64Cu-M5A)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol
History of allergic reactions attributed to compounds of similar chemical or biologic composition to magnetic resonance (MR) contrast material
History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol or other agents used in the study
History of allergic reactions to IV contrasts or reactions attributed to compounds of similar chemical or biologic composition to Ga-68-DOTA-TOC or 18F-FLT used in study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including those patients with a history of iodide or seafood allergy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to FDHT
History of allergic reactions attributed to compounds of similar chemical or biologic composition to L-[methyl-11C]methionine
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lorlatinib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic acid (ALA)
Women with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to isosulfan blue or indocyanine green or other agents used in this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ALA; patients should refrain from use of other potential phototoxic substances (e.g. tetracyclines, sulfonamides, fluoroquinolones, hypericin extracts) for 72 h
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Eovist
History of allergic reactions to compounds of similar chemical composition to ALA
History of allergic reaction to compounds of similar composition to ferumoxytol (e.g. IV iron)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin D
History of allergic reactions attributed to compounds of similar chemical or biologic composition to idelalisib
History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide or other agents used in study
The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or cisplatin.
The participant has a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or carboplatin.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, ipilimumab, or blinatumomab
History of allergic reactions/hypersensitivity attributed to compounds of similar chemical or biologic composition to CE/BZA; (I.e. same class of drug as CE/BZA)
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab.